Literature DB >> 31407210

Crataegus mexicana (Tejocote) Exposure Associated with Cardiotoxicity and a Falsely Elevated Digoxin Level.

Katherine G Palmer1, Jacob A Lebin2, Michael T Cronin3, Suzan S Mazor4,5, Rebekah A Burns4.   

Abstract

INTRODUCTION: A species of hawthorn, Crataegus mexicana (tejocote), has been marketed as a weight-loss supplement that is readily available for purchase online. While several hawthorn species have shown clinical benefit in the treatment of heart failure owing to their positive inotropic effects, little is known about hawthorn, and tejocote in particular, when consumed in excess. We describe a case of tejocote exposure from a weight-loss supplement resulting in severe cardiotoxicity. CASE REPORT: A healthy 16-year-old girl presented to an emergency department after ingesting eight pieces of her mother's tejocote root weight-loss supplement. At arrival, she was drowsy, had active vomiting and diarrhea, and had a heart rate of 57 with normal respirations. Her initial blood chemistries were unremarkable, except for an elevated digoxin assay of 0.7 ng/mL (therapeutic range 0.5-2.0 ng/mL). All other drug screens were negative. She later developed severe bradycardia and multiple episodes of hypopnea that prompted a transfer to our institution, a tertiary pediatric hospital. Her ECG demonstrated a heart rate of 38 and Mobitz type 1 second-degree heart block. She was subsequently given two vials of Digoxin Immune Fab due to severe bradycardia in the setting of suspected digoxin-like cardiotoxicity after discussion with the regional poison control center. No clinical improvement was observed. Approximately 29 hours after ingestion, subsequent ECGs demonstrated a return to normal sinus rhythm, and her symptoms resolved. DISCUSSION: Tejocote root toxicity may cause dysrhythmias and respiratory depression. Similar to other species of hawthorn, tejocote root may cross-react with some commercial digoxin assays, resulting in a falsely elevated level.

Entities:  

Keywords:  Cardiovascular toxicity; Crataegus; Digoxin; Hawthorn; Tejocote

Mesh:

Substances:

Year:  2019        PMID: 31407210      PMCID: PMC6825057          DOI: 10.1007/s13181-019-00727-w

Source DB:  PubMed          Journal:  J Med Toxicol        ISSN: 1556-9039


  10 in total

1.  Hawthorn.

Authors:  Qi Chang; Zhong Zuo; Francisco Harrison; Moses Sing Sum Chow
Journal:  J Clin Pharmacol       Date:  2002-06       Impact factor: 3.126

2.  Digoxin toxicity.

Authors:  Deepika Thacker; Jayendra Sharma
Journal:  Clin Pediatr (Phila)       Date:  2007-04       Impact factor: 1.168

3.  Interference of hawthorn on serum digoxin measurements by immunoassays and pharmacodynamic interaction with digoxin.

Authors:  Amitava Dasgupta; Laura Kidd; Brian J Poindexter; Roger J Bick
Journal:  Arch Pathol Lab Med       Date:  2010-08       Impact factor: 5.534

Review 4.  Acute pediatric digoxin ingestion.

Authors:  M A Gittelman; M Stephan; H Perry
Journal:  Pediatr Emerg Care       Date:  1999-10       Impact factor: 1.454

5.  The efficacy and safety of Crataegus extract WS 1442 in patients with heart failure: the SPICE trial.

Authors:  Christian J F Holubarsch; Wilson S Colucci; Thomas Meinertz; Wilhelm Gaus; Michal Tendera
Journal:  Eur J Heart Fail       Date:  2008-11-18       Impact factor: 15.534

Review 6.  Hawthorn extract for treating chronic heart failure.

Authors:  M H Pittler; R Guo; E Ernst
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23

7.  Enzalutamide and analytical interferences in digoxin assays.

Authors:  Marie Deguigne; Marion Brunet; Chadi Abbara; Alain Turcant; Gaël Le Roux; Bénédicte Lelièvre
Journal:  Clin Toxicol (Phila)       Date:  2018-05-09       Impact factor: 4.467

Review 8.  Adverse-event profile of Crataegus spp.: a systematic review.

Authors:  Claudia Daniele; Gabriela Mazzanti; Max H Pittler; Edzard Ernst
Journal:  Drug Saf       Date:  2006       Impact factor: 5.228

Review 9.  Overviews of Biological Importance of Quercetin: A Bioactive Flavonoid.

Authors:  Alexander Victor Anand David; Radhakrishnan Arulmoli; Subramani Parasuraman
Journal:  Pharmacogn Rev       Date:  2016 Jul-Dec

Review 10.  Benefit-Risk Assessment of Crataegus Extract WS 1442: An Evidence-Based Review.

Authors:  Christian J F Holubarsch; Wilson S Colucci; Jaan Eha
Journal:  Am J Cardiovasc Drugs       Date:  2018-02       Impact factor: 3.571

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.